Design Therapeutics Inc (DSGN)
3.345
+0.10
(+3.24%)
USD |
NASDAQ |
Jun 27, 16:00
3.345
0.00 (0.00%)
After-Hours: 20:00
Design Therapeutics Cash from Financing (Quarterly): 0.02M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.02M |
| December 31, 2023 | 0.501M |
| September 30, 2023 | 0.013M |
| June 30, 2023 | 0.21M |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.13M |
| September 30, 2022 | 0.151M |
| June 30, 2022 | -0.202M |
| March 31, 2022 | 0.156M |
| Date | Value |
|---|---|
| December 31, 2021 | 0.193M |
| September 30, 2021 | 0.03M |
| June 30, 2021 | 0.005M |
| March 31, 2021 | 378.98M |
| December 31, 2020 | 0.001M |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 44.53M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.202M
Minimum
Jun 2022
378.98M
Maximum
Mar 2021
24.98M
Average
0.03M
Median
Sep 2021
Cash from Financing (Quarterly) Benchmarks
| Biogen Inc | -439.60M |
| AbbVie Inc | 10.82B |
| PTC Therapeutics Inc | 0.54M |
| Revance Therapeutics Inc | 92.83M |
| Context Therapeutics Inc | -- |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -12.44M |
| Cash from Investing (Quarterly) | 20.62M |
| Free Cash Flow | -53.94M |
| Free Cash Flow Per Share (Quarterly) | -0.2237 |
| Free Cash Flow Yield | -28.73% |